Stockscreener 앱 받기
0.6274
4.78%
-0.0315
시간 외 거래:
.62
-0.0074
-1.18%
전일 마감가:
$0.6589
열려 있는:
$0.67
하루 거래량:
1.35M
Relative Volume:
0.41
시가총액:
$2.99M
수익:
-
순이익/손실:
$-21.33M
주가수익비율:
-0.00552
EPS:
-113.7479
순현금흐름:
$-9.12M
1주 성능:
+16.19%
1개월 성능:
-6.41%
6개월 성능:
-41.58%
1년 성능:
-84.62%
1일 변동 폭
$0.615
$0.6997
1주일 범위
$0.518
$0.74
52주 변동 폭
$0.4728
$6.30
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
명칭
Zyversa Therapeutics Inc
전화
908-370-5102
주소
217 W. MAIN STREET, SOMERVILLE
ZVSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
0.6274 | 2.58M | 0 | -21.33M | -9.12M | -113.75 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Zyversa Therapeutics Inc 주식(ZVSA)의 최신 뉴스
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World
ZVSA: ZyVersa Therapeutics' IC 100 Shows Promise in PD Treatment - GuruFocus
ZyVersa’s IC 100 shows promise in Parkinson’s treatment By Investing.com - Investing.com India
ZyVersa Therapeutics highlights publication of data on IC 100 - TipRanks
ZyVersa’s IC 100 shows promise in Parkinson’s treatment - Investing.com Australia
ZyVersa Therapeutics Highlights Published Study Reinforcing - GlobeNewswire
Breakthrough Study Reveals Key to Fighting Parkinson's: ZyVersa's Novel Drug Shows Promise in $13B Market - Stock Titan
ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100 - Nasdaq
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress - GlobeNewswire
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps - MSN
Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps By Stocktwits - Investing.com India
ZyVersa Unveils Groundbreaking Potential of Inflammasome - GlobeNewswire
ZyVersa Therapeutics announces developments on inflammasome inhibitors - TipRanks
ZyVersa progresses with obesity inflammation treatment - Investing.com Australia
ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity - marketscreener.com
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update - Stock Titan
ZyVersa Therapeutics Inc [ZVSA] is -36.75% lower this YTD. Is it still time to buy? - dbtnews.com
ZyVersa Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
How does ZVSA’s price to cash per share ratio compare in the market? - uspostnews.com
Study finds inflammation-targeting drug has Parkinson’s potential - Longevity.Technology
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's - GuruFocus
Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation - marketscreener.com
ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's Treatment | ZVSA Stock News - GuruFocus
ZyVersa Therapeutics Announces Promising Data for Inflammasome ASC Inhibitor IC 100 in Parkinson's Disease Research - Nasdaq
ZyVersa Therapeutics Announces Published Data Showing - GlobeNewswire
Game-Changing Parkinson's Treatment: Nature Study Reveals Drug's Dual-Action Against Disease Progression - Stock Titan
ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa progresses with novel inflammation treatment - Investing.com
ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire
ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan
ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN
Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
ZyVersa CEO outlines progress in kidney disease drug development - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks
ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus
ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus
ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus
ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire
ZyVersa Therapeutics appoints new accounting firm - Investing.com
ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline By Investing.com - Investing.com South Africa
ZVSA stock touches 52-week low at $0.58 amid sharp annual decline - Investing.com Australia
Zyversa Therapeutics Inc (ZVSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):